Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients.
Gisella GuerreraAlessandra MandelliAnnamaria FinardiMario OrricoSilvia D'OrsoMario PicozzaMaddalena NovielloValeria BerettaBruno BonettiMassimiliano CalabreseDamiano MarastoniNicola De RossiRuggero CapraMarco SalvettiMaria Chiara BuscarinuMatilde IngleseAntonio UccelliLucia MoiolaCatarina RaposoErwan Muros-Le RouzicRosetta PedottiMassimo FilippiChiara BoniniLuca BattistiniGiovanna BorsellinoRoberto FurlanPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
B-cell depletion using ocrelizumab does not impair the development of long-lasting anti-SARS-CoV-2 T-cell responses.